Healthcare Enterprise Group market a product called "Ebiox" which is one of a very few that can kill most bacteria including the MRSA superbug. HCEG has contracts with some NHS hospitals at present, but given the recent and current news and public attention, HCEG should be a good bet for a steady rise as more places seek to cut the number of casualties from this infection. HCEG also market abroad in USA, so the potential market for this unique product is massive indeed.

Well worth a punt IMHO

Check it out for yourself

There are other threads about HCEG. Indeed they are worth a punt, and have recently (if I remember correctly) signed some small deals with the NHS. But a major contract is needed to boost these..... it seems no-one has noticed that Ebiox will kill MRSA! Yet.

skids

I searched for HCEG but nothing came up so the threads (which I knew existed previously) may have disappeared. These are worth researching by anyone looking medium to long term for a sound investment.

TRY CAPS

Whilst it may be true Ebiox "kills all bugs including MRSA" there is no evidence a that I'm aware of, that using Ebiox in a NHS hospital will make the "MRSA epidemic" go away.
The reason for this seems to be lack of publicity by HCEG (ie sitting on their hands,) and Regulations in NHS hospitals to use ancient alcohol-based hand-wash that ruins your skin - so it's use it not frequent.
Furthermore Hospitals are run for the benefit of the administrators, not the patients and cleaning the wards is conducted by low-paid staff who are probably overworked.
The MRSA outbreak has become newsworthy; as a result Health Officials are scurrying about - again we have an industry that has no chain of blame - so the buck is passed from one to another and no-one gets down to fundamentals.

Finally, the "reason" for MRSA is over-use of antibiotics - something that was a worry over 10 years ago - now we reap the result.
Whilst Ebiox might prevent the spread of MRSA and indeed kill it when it land on your hands - that is not the same as eradicating it from our hospitals.
Link that to HCEG ineffective management and you have the formula for a slide in the shares - if they can't shift this stuff when it's wanted, what hope is there? It makes me suspicious that the product is not the answer to MRSA and management knows this - purely IMHO, but that's what this scenario looks like.

News today (Friday) is that the NHS has found that regular hand-washing reduced MRSA - well what a surprise, but that's not the same as eradicating it, is it?
I still hold HCEG.

suggest you all look at Articles & Anylisis thread on HCEG over on ADFVN http://www.advfn.com/cmn/fbb/thread.php3?id=6399024

itsmeagain, I would like to see the article but do not use the ADVFN site, would you like to post the article/Anyl. here please?

Is this the one on the news the other night, you have to squib it up your nose and activate with light?
It did look interesting but as we know these are called superbugs because they evolve, mutate and become resistant. They have always been around in hospitals and they do make me think twice about a hospital job.
I would like to see the link too please.

I've been in this share and out again , not because I did not thin k it has a future but because there are several BILLION shares in issue - to make this move you need a 50 to 100 million share trade day

Gary K,here is a some info but the articles & analysis is fukk of info,hope below isn't too much and informs you of score. (Courtesy of Murraymint)

Fighting MRSA by Mike Walters

What follows is not an investment comment. It is a background document on MRSA and how it might be tackled, with reference to Ebiox. It comes from Gordon Wood, a director of Healthcare Enterprise Group. He is happy to see it reproduced here, and to be used as you wish. I am reproducing it in view of the interest aroused by my comments earlier this week, and to help support those who are pressing their MPs and others to get the authorities to act, and act quickly, in bringing Ebiox into the fight to make our hospitals safer.

Hospital acquired infections (HAI) are those that are neither present or incubating when a patient enters hospital. Their effects vary from discomfort for the patient, to prolonged or permanent disability, and even death.

Infections such as caused by Methicillin resistant staphylococcus aureus, MRSA are more commonly known as a superbug.

Best estimates suggest that each year there are at least 100,000 cases cases of HAI in England causing around 5,000 deaths, and the cost to the National Health Service may be as much as GBP 1 billion a year.

A survey showed Britain had the worst record for infection in Europe - patients here are 40 times more likely to catch MRSA than those in Holland.

The vast majority of HAIs are caused by high patient throughput, inadequate hygiene and misuse of disinfectants and antibiotics.

What are the problem microorganisms ?

Streptococcus pyrogenes is a common cause of sore throat. Althogh not very common the severity of the illness makes it an important pathogen to eradicate.

Entrococcus faecium has emerged as an important pathogen which is acquiring resistance to a range of antimicrobials.

Clostridium difficile and Clostridium perfingens are spore forming bacteria and are the cause of much morbidity in elderly hospitalized patients.

Entrobacter cloacae, Gram negative species such as Acinetobacter, Pseudomonas and Burkholderia pose a serious threat to hospitalized patients.

However Staphylococcus aureus is the most important noscomial pathogen causing mortality in hospitalized patients. Strains resistant to antibiotics (MRSA) are a serious increasing problem and Doctors are very worried about the future with MRSA.

What is MRSA?

Staphylococcus is a family of common bacteria often found in 20-30% of the throats, noses and skin of healthy people.

MRSA stands for methicillin-resistant Staphylococcus aureus, but is shorthand for any strain of Staphylococcus bacteria which is resistant to one or more conventional antibiotics such as methicillin.

Some bacterial strains' genetic makeup will give them a slight advantage when it comes to fighting off antibiotic attack. So when weaker strains encounter antibiotics, they die, while these naturally resistant strains may prove harder to kill. Bacterial genes have an inbuilt self defence mechanism and are constantly mutating.

The number of reports of MRSA infections rises year by year - and the latest evidence suggests that deaths due to MRSA are increasing at a similar rate.

Already, the spectre of a bug resistant to all antibiotics is approaching.
In Japan it is understood that vancomycin resistant Staphylococcus Aureus VRSA, has acquired resistance to the drug considered the "last line of defence" when all other antibiotics have failed.

The UK has already seen several cases of GISA, or glycopeptide intermediate Staphylococcus aureus, a kind of "halfway house" between MRSA and VRSA, which has developed a resistance to antibiotics of the vancomycin family.

Although new antibiotics are being developed all the time, pessimistic experts believe it is only a matter of time at current rates until virtually every weapon in the pharmaceutical arsenal is nullified.

Why does MRSA exist ?

One reason behind their swift evolution into "superbugs" is the overuse of antibiotics, both in human and veterinary medicine.

Another, possibly more mysterious reason, is from dirty surfaces and lack of basic hygiene, inadequate cleaning and the casual use of disinfectants.

All surfaces maintain a molecular Bio Film where bacteria living or landing on a surface secrete a polysaccharide (sugar) complex. As more land and grow this living wallpaper thrives.

This Bio Film, which is almost insoluble, protects the micro organisms from attack by surface agents. Bio Films are not static but in a constant state of movement and change.

There is a constant re allocation of microbic species. By interfering with this constant change by the use of only partially effective disinfectants then an out of balance scene will develop and resistant microbes eg MRSA will attain supremacy.

Likewise the use of traditional cleaning detergents will leave an invisible nutrient rich film which will enhance the Bio Film and feed the microbic species, possibly to dangerous levels. The film will then dry out and encapsulated micro species will be carried by air currents until they land on a surface or an open wound.

Finally it is believed that MRSA has changed it now can actually penetrate and live inside certain other bacteria and possibly micro fungi. This isolates them from attack.

Why is it so dangerous ?

It is a fact of life in the NHS that patients are at higher than normal risk of picking up an infection on the wards.

This is for two reasons - firstly, that the population in hospitals tends to be older, sicker and weaker than the general population, making them more vulnerable to the infection. Also, there are by definition more people with diseases and open wounds in hospital, and more MRSA carriers. Often, hospital staff are carriers of the bug, without realising it.

Secondly, conditions in hospitals, which involve a great many people living together, create complex ecosystems whereby patients live in an unbalanced symbiosis with microbes within the building structure. This is the perfect environment for the transmission of all manner of infections.

What can we do about it now ?

The MRSA problem is not curing with antibiotics but changing cleaning and hygiene products and procedures to match the modern demands within a health care establishment. Strict hygiene is the best defense and falls into two categories Hand Hygiene and Surface Hygiene.

Hand Hygiene

This is essential, it is difficult to over emphasise the importance of good hand hygiene. Noscomial pathogens are transmitted via the hands of health care workers and hand hygiene is considered a leading preventative measure to reduce cross contamination in Healthcare settings.

Two different types of hand hygiene procedures are recommended to be followed.

1. Washing with an antibacterial soap or scrub.
2. Regular application of a hand disinfectant between patients and when hands are not dirty.

Hand washing on a regular basis is not always practical and can cause Irritant Dermatitis, hence the need for top up protection with the hand disinfectant.

Hand Hygiene agents should have anti microbial efficacy against noscomial pathogens. In Europe, the state of the art protocols to test their efficacy are referred to as the European norms (EN).

prEN12054 is a standard for establishing whether a Hand Wash or a Hand Disinfectant does have bactericidal activity under laboratory conditions. The test organisms are Escherichia coli, Pseudomonas aeruginosa, Entrococcus hirae and Staphylococcus aureus. Should a product comply with the test requirements, it can be considered to possess bactericidal activity.

En1499 (Phase 2 step 2) is the standard by which the efficacy of Hand Scrubs are tested under practical conditions where disinfection is medically indicated. The test comprises artificially contaminating hands of volunteers, before and after application of a Hand Scrub with test and reference products. To pass the test the reduction factor of the test product should be significantly superior to the reference product.

EN1500 is the standard by which the efficacy of Hand disinfectants are tested under practical conditions by comparison with the reference disinfectant (2-propanol, 60% volume per volume) tested on Eshererichia coli K12. The tested product should not be less effective that the reference alcohol.

However any Hand Hygiene agent, as it will be used on a regular basis, should be mild to the skin and provide low skin irritancy. Disinfection products that pass the above tests normally contain alcohol, unfortunately alcohol has little if any residual effect and after immediate application offers little protection, in addition alcohol causes skin irritancy and dryness and can lead to personnel avoiding their use.

Ebiox V2 Hand Scrub fully complies with prEN 12054 and exceeds the standard EN1499.

Ebiox V2 Hand Disinfectant fully complies with prEN12054 and EN1500.

Both products have been independently tested at the Hospital Infection Research Laboratory in Birmingham and are proven to eradicate MRSA from hands.

V2 Hand Hygiene products are unique they have a residual long lasting effect, do not contain alcohol and as such do not cause skin irritations, are lotions with moisturizers BUT STILL OFFER THE PROTECTION REQUIRED.

Surface Hygiene

This includes locker tops adjacent to patients, mattresses, floors, walls and other patient contact areas.

It is the efficient removal of the pathogen loaded Bio Film which is CRITICAL. This will eliminate the living wallpaper which is the source that harbours protects and feeds MRSA and provides the protective shell for the self generation of mutant and resistant bacteria

Conventional detergents and disinfectants have to be discarded, they simply do not have the power to deal with the rapidly changing bio-protective systems evolved by micro organisms.

Trionic Plus is a new technology surface active agent which will penetrate and completely remove the bio film and embedded pathogens. These micro organisms are then destroyed by the active ingredients in Trionic Plus which are effective against a broad range of bacteria and viruses. Trionic Plus in this form is ideal for regular use to clean, deodorise and sanitise surfaces on a general basis and maintain an hygienic environment.

When more than routine cleaning is required in either a sensitive or high risk area, in the event of a disease outbreak or a specific need to immediately eradicate a known pathogen Trionic Plus can be ACTIVATED to create a Terminal Disinfectant.

Trionic Plus when activated is probably the most powerful and safe oxidising biocide available containing nine different oxidants. Applied to any hard surface it will immediately eradicate bacteria, viruses, fungi and spores. It will eradicate MRSA and kill Parvovirus in seconds. Proven more effective than toxic Gluteraldehyde, corrosive Peracetic acid, Chlorine, Isopropyl alcohol and Ethanol whilst being user and environmentally friendly and safe to use.

Trionic Plus when activated will give total disinfection under extreme conditions.

The Hospital Infection Research Laboratory carried out an Assessment test to assess the Bio Film removal effect of Trionic Plus in normal use and the killing effect when activated.

Pseudomonas aeruginosa NCTC 6749, Staphylococcus aureus NCTC 10788 and Methicillin Resistant Staphylococcus aureus NCTC 12493 were the test bacteria.

These were dried onto a stainless steel disks and immersed for a range of contact times. The number or remaining test organisms were counted to ascertain the removal/killing efficacy.

Trionic Plus outperformed the reference product and achieved a greater than 4 log reduction in test soiling which is equivalent to more 99.99% removal.

Trionic plus when activated killed the test organisms below non detectable level in less than 15 seconds.

Note: I believe Mike is happy to see this made public to help those writing to local MPs etc.

Independent

Poised to clean up
By Stephen Foley
19 July 2004

The government last week put a crackdown on hospital cleanliness at the centre of its fight against the superbug MRSA, which kills an estimated 5,000 in-patients every year in the UK. With hygiene inspections being stepped up and patients urged to shop dirty doctors and nurses, it seems the ideal time for Healthcare Enterprises to begin marketing its range of heavy-duty handwashes and lotions, which kill MRSA. The product, called Ebiox, was developed at Porton Down as an offshoot of the biological warfare programme. Next week, Healthcare is expected to announce that the complete hand cleansing range has passed NHS laboratory tests, proving that Ebiox will completely eradicate bacteria on the hands and the hand lotion will keep hands bacteria free for much longer than existing alcohol-based products. In addition, keep an ear out for results from US hospitals too, which are due in the next few weeks and could help open up that much bigger market for the product.

hope this is the start need funds for my pension

Volume Leaders

EPIC Name Price Volume
1 (1) VOD Vodafone Grp. 117.75 57,329,900
2 (2) SCR Securicor 131.25 47,629,900 A
3 (3) GSK Glaxosmithkline 1037.0 29,307,100
4 (4) HCEG Healthcare Ent. 1.745 25,540,600

John Reid has just been on the Jeremy Vine show on Radio 2 discussing MRSA.
They also had the chairman of the MRSA support group on.
The key points which struck me were:

The chairman of the MRSA support association said:
1) No.1 question he gets asked is how can I sue the NHS?
2) Research has shown MRSA can survive on a speck of dust for at least 3 months!
John Reid said:
3) Improved cleanliness most important measure with patients having more control.
4) Old hospitals, staff shortages and long waiting lists contribute to the problem.

Historical Prices - HCEG.L (HEALTHCARE ENTERPRISE GROUP PLC) As of 16-Jul-04
Date Open High Low Close Volume Adj. Close*
16-Jul-04 1.65 1.65 1.65 1.63 3,866,620 1.63
15-Jul-04 1.63 1.65 1.63 1.69 15,768,800 1.69
14-Jul-04 1.60 1.62 1.60 1.60 22,407,300 1.60
13-Jul-04 1.59 1.60 1.59 1.59 13,180,700 1.59
12-Jul-04 1.55 1.59 1.55 1.57 7,310,820 1.57
09-Jul-04 1.59 1.59 1.55 1.57 2,109,300 1.57
08-Jul-04 1.59 1.60 1.59 1.60 1,925,200 1.60
07-Jul-04 1.59 1.59 1.59 1.57 1,051,640 1.57
06-Jul-04 1.62 1.62 1.59 1.55 1,156,940 1.55
05-Jul-04 1.65 1.65 1.62 1.58 1,512,790 1.58
02-Jul-04 1.63 1.66 1.63 1.60 1,836,850 1.60
01-Jul-04 1.65 1.65 1.63 1.60 685,322 1.60
30-Jun-04 1.65 1.65 1.65 1.50 3,605,480 1.50
29-Jun-04 1.62 1.65 1.62 1.60 12,852,300 1.60
28-Jun-04 1.72 1.72 1.62 1.60 4,897,370 1.60
25-Jun-04 1.71 1.72 1.71 1.68 1,693,590 1.68
24-Jun-04 1.73 1.73 1.71 1.69 856,672 1.69
23-Jun-04 1.74 1.74 1.73 1.68 1,525,730 1.68
22-Jun-04 1.75 1.75 1.74 1.70 504,376 1.70
21-Jun-04 1.76 1.76 1.74 1.72 1,311,680 1.72
18-Jun-04 1.76 1.76 1.76 1.73 1,578,600 1.73
17-Jun-04 1.75 1.76 1.75 1.76 1,702,310 1.76
16-Jun-04 1.75 1.75 1.75 1.74 4,647,210 1.74
15-Jun-04 1.76 1.76 1.74 1.70 1,920,250 1.70
14-Jun-04 1.76 1.76 1.76 1.76 4,275,760 1.76
11-Jun-04 1.76 1.76 1.76 1.73 1,669,900 1.73
10-Jun-04 1.76 1.76 1.76 1.76 1,122,290 1.76
09-Jun-04 1.73 1.76 1.73 1.73 7,197,510 1.73
08-Jun-04 1.77 1.77 1.75 1.70 2,821,860 1.70
07-Jun-04 1.77 1.77 1.76 1.75 9,384,000 1.75
04-Jun-04 1.70 1.74 1.70 1.71 7,705,450 1.71
03-Jun-04 1.69 1.70 1.69 1.70 23,205,300 1.70
02-Jun-04 1.72 1.72 1.68 1.71 3,403,110 1.71
01-Jun-04 1.67 1.70 1.66 1.72 4,607,880 1.72
28-May-04 1.73 1.73 1.70 1.70 1,623,200 1.70
27-May-04 1.73 1.73 1.73 1.70 1,064,460 1.70
26-May-04 1.67 1.73 1.67 1.70 6,867,420 1.70
25-May-04 1.67 1.67 1.67 1.63 355,259 1.63
24-May-04 1.67 1.67 1.67 1.63 1,991,160 1.63
21-May-04 1.68 1.68 1.67 1.63 2,067,710 1.63
20-May-04 1.68 1.68 1.68 1.69 1,429,830 1.69
19-May-04 1.65 1.68 1.65 1.70 9,788,380 1.70
18-May-04 1.67 1.67 1.65 1.64 2,969,630 1.64
17-May-04 1.75 1.75 1.67 1.65 4,668,740 1.65
14-May-04 1.74 1.76 1.73 1.73 7,661,440 1.73
13-May-04 1.75 1.75 1.74 1.77 3,645,650 1.77
12-May-04 1.58 1.76 1.58 1.79 25,250,800 1.79
11-May-04 1.74 1.74 1.65 1.63 8,599,630 1.63
10-May-04 1.88 1.88 1.76 1.73 7,016,340 1.73
07-May-04 1.96 1.96 1.88 1.86 4,906,980 1.86
06-May-04 2.00 2.00 1.96 2.03 4,511,580 2.03
05-May-04 2.03 2.04 2.00 1.95 4,602,610 1.95
04-May-04 2.04 2.04 2.03 1.98 3,354,420 1.98
30-Apr-04 2.04 2.04 2.04 2.04 4,409,020 2.04
29-Apr-04 2.06 2.06 2.04 2.02 5,025,910 2.02
28-Apr-04 2.04 2.06 2.04 2.01 7,749,020 2.01
27-Apr-04 1.98 2.04 1.98 2.02 12,025,800 2.02
26-Apr-04 1.96 1.99 1.96 1.93 61,091,800 1.93
23-Apr-04 1.93 1.95 1.93 1.94 3,485,050 1.94
22-Apr-04 1.98 1.98 1.93 1.93 5,661,380 1.93
21-Apr-04 2.07 2.07 1.95 1.97 10,170,500 1.97
20-Apr-04 2.09 2.09 2.06 2.09 6,043,630 2.09
19-Apr-04 2.09 2.09 2.09 2.10 14,032,800 2.10
16-Apr-04 2.10 2.10 2.10 2.11 12,205,500 2.11
15-Apr-04 2.09 2.10 2.09 2.11 29,013,900 2.11
14-Apr-04 2.07 2.09 2.07 2.07 21,360,200 2.07
13-Apr-04 2.06 2.07 2.04 2.05 27,390,600 2.05
08-Apr-04 2.10 2.10 2.05 2.05 11,594,000 2.05
07-Apr-04 2.06 2.06 2.06 2.04 1,455,560 2.04
06-Apr-04 2.09 2.09 2.06 2.05 4,585,790 2.05
05-Apr-04 2.09 2.12 2.09 2.09 5,538,830 2.09
02-Apr-04 2.07 2.08 2.07 2.03 4,240,940 2.03
01-Apr-04 2.08 2.08 2.07 2.03 5,256,400 2.03
31-Mar-04 2.09 2.09 2.08 2.03 3,048,350 2.03
30-Mar-04 2.08 2.11 2.08 2.05 12,141,700 2.05
29-Mar-04 2.17 2.17 2.08 2.05 6,918,220 2.05
26-Mar-04 2.20 2.20 2.18 2.15 5,579,970 2.15
25-Mar-04 2.21 2.23 2.20 2.18 8,112,760 2.18
24-Mar-04 2.26 2.26 2.23 2.23 6,610,410 2.23
23-Mar-04 2.27 2.28 2.26 2.23 5,155,810 2.23
22-Mar-04 2.29 2.30 2.27 2.23 11,314,100 2.23
19-Mar-04 2.33 2.33 2.29 2.25 12,198,300 2.25
18-Mar-04 2.29 2.33 2.29 2.34 39,540,600 2.34
17-Mar-04 2.22 2.22 2.19 2.15 5,199,800 2.15
16-Mar-04 2.29 2.29 2.23 2.20 7,122,200 2.20
15-Mar-04 2.26 2.29 2.26 2.30 28,127,300 2.30
12-Mar-04 2.19 2.23 2.17 2.24 14,710,500 2.24
11-Mar-04 2.34 2.34 2.17 2.15 18,353,000 2.15
10-Mar-04 2.31 2.34 2.31 2.33 22,227,400 2.33
09-Mar-04 2.34 2.34 2.22 2.25 12,444,500 2.25
08-Mar-04 2.24 2.35 2.24 2.31 29,056,500 2.31
05-Mar-04 2.16 2.23 2.15 2.23 216,020,992 2.23
04-Mar-04 2.21 2.21 2.09 2.16 27,683,700 2.16
03-Mar-04 2.23 2.23 2.23 2.24 12,596,300 2.24
02-Mar-04 2.40 2.40 2.22 2.24 48,003,600 2.24
01-Mar-04 2.27 2.46 2.27 2.39 131,588,000 2.39
27-Feb-04 2.14 2.22 2.14 2.24 95,151,400 2.24
26-Feb-04 2.12 2.14 2.12 2.12 74,079,200 2.12
25-Feb-04 1.98 1.99 1.98 1.99 14,562,300 1.99
24-Feb-04 1.96 1.98 1.96 1.97 23,115,500 1.97
23-Feb-04 1.94 1.96 1.94 1.97 9,733,260 1.97
20-Feb-04 1.94 1.94 1.94 1.94 2,175,960 1.94
19-Feb-04 1.94 1.94 1.94 1.93 2,815,890 1.93
18-Feb-04 1.95 1.98 1.94 1.95 6,792,280 1.95
17-Feb-04 1.92 1.93 1.92 1.92 14,041,400 1.92
16-Feb-04 1.93 1.95 1.92 1.95 13,379,100 1.95
13-Feb-04 1.86 1.93 1.86 1.93 21,548,400 1.93
12-Feb-04 1.82 1.84 1.80 1.85 12,474,500 1.85
11-Feb-04 1.83 1.87 1.82 1.78 7,612,080 1.78
10-Feb-04 1.88 1.88 1.86 1.90 7,391,920 1.90
09-Feb-04 1.88 1.88 1.88 1.88 15,660,600 1.88
06-Feb-04 1.88 1.89 1.87 1.87 9,835,470 1.87
05-Feb-04 1.89 1.89 1.88 1.88 6,973,830 1.88
04-Feb-04 1.89 1.89 1.89 1.91 5,505,080 1.91
03-Feb-04 1.91 1.91 1.88 1.88 3,287,560 1.88
02-Feb-04 1.91 1.92 1.91 1.91 10,910,200 1.91
30-Jan-04 1.88 1.88 1.88 1.88 5,791,940 1.88
29-Jan-04 1.88 1.88 1.88 1.87 3,542,200 1.87
28-Jan-04 1.88 1.88 1.88 1.88 27,853,900 1.88
27-Jan-04 1.88 1.88 1.88 1.87 2,103,340 1.87
26-Jan-04 1.88 1.88 1.88 1.88 3,289,680 1.88
23-Jan-04 1.88 1.88 1.88 1.87 59,942,400 1.87
22-Jan-04 1.88 1.88 1.88 1.87 6,141,100 1.87
21-Jan-04 1.88 1.88 1.88 1.88 4,356,900 1.88
20-Jan-04 1.88 1.91 1.88 1.90 51,900,100 1.90
19-Jan-04 1.88 1.89 1.88 1.90 5,115,060 1.90

I've heard 2 discussions about MRSA on the radio recently. The first was about Energy Technique, the second just a general Today chat, anchorman and parliamentary head nurse. Why on earth didn't they mention HCEG, does the press not know about it. It's time they did, not because I own a few shares, I've seen what this hospital administered bug can do.

15000000 t trade at 1.67p,must of been expecting a rush and that it certainly did.Lookin good for the comming weeks.

15000000 t trade at 1.67p,must of been expecting a rush and that it certainly did.Lookin good for the comming weeks.

It will be interesting to see how this stock behaves tomorrow. It closed at 2.39p on March 1st and with the latest NHS scandal going on, I've every reason to believe we should see that price again.

For those who missed it, it's worth repeating the Independent's article:

Independent
By Stephen Foley
19 July 2004
Poised to clean up

The government last week put a crackdown on hospital cleanliness at the centre of its fight against the superbug MRSA, which kills an estimated 5,000 in-patients every year in the UK. With hygiene inspections being stepped up and patients urged to shop dirty doctors and nurses, it seems the ideal time for Healthcare Enterprises to begin marketing its range of heavy-duty handwashes and lotions, which kill MRSA. The product, called Ebiox, was developed at Porton Down as an offshoot of the biological warfare programme. Next week, Healthcare is expected to announce that the complete hand cleansing range has passed NHS laboratory tests, proving that Ebiox will completely eradicate bacteria on the hands and the hand lotion will keep hands bacteria free for much longer than existing alcohol-based products. In addition, keep an ear out for results from US hospitals too, which are due in the next few weeks and could help open up that much bigger market for the product.

http://news.independent.co.uk/business/analysis_and_features/story.jsp?story=542424

Seems Ebiox is not the only product capable of killing this superbug.http://www.eveningtimes.co.uk/hi/news/5028698.html

It's about time this management started selling the stuff. If they can't shift it when there is a demand (news every day!)-what hope have they when there are competitors snapping at their heels? - I wonder if they have a belief that this is the only product on the planet, that will do the job - so they are taking a softly, softly course. That is not the case! Very good hygiene will do the job as well - only staff will have sore hands and the time taken (between patients) will further slow down hospitals.
I hold HCEG because of the Product - that gets 8/10 but the management looks poor on the evidence so far, so maybe 2/10 - giving a measly 5/10 AND could do better score........all IMHO but that is what counts in my home.
Recent large trading volume (Monday) is not much compared with the huge number of shares out there and I suspect the Management has covered themselves in Options. The facts will be known in time, but it's not looking like a 10-bagger anymore.
On another note; the MRSA bug is gaining, which is a pity.

Maybe the management are waiting for Ebiox to pass the NHS tests, mentioned in the Independent article, before they start promoting it. Hopefully the results from US hospitals will be positive as well and the management will start breaking into the American market.

Just to keep you all on the straight and narrow,

Healthcare Enterprise Group PLC
26 February 2004

Healthcare Enterprise Group PLC

Ebiox test results


Healthcare Enterprise Group PLC (HCEG), the healthcare products and services
company, announces the conclusion of controlled tests carried out by the NHS
Hospital Infection Research Laboratory City Hospital, Birmingham on its Ebiox
decontamination products.


The results show Ebiox to be an effective solution for eradicating bacteria,
including the MRSA 'Superbug' in two key areas: hand contact (washing) and cross
contamination from bacteria-laden work surfaces and floors.


The Department of Health has recognised hand decontamination, before and after
patient contact, as 'vital' to the control of hospital acquired infections*. It
has also identified that cleaning and disinfecting protocols are a key to
'reducing reservoirs of infection in hospitals'*.


The Laboratory tests report that the Ebiox handrub and handwash products were
'significantly more effective' than the standard reference product for the test
in eradicating bacteria, including MRSA from the hands.


As a general cleaning detergent for hard surfaces and flooring, Ebiox Trionic
Plus was proven to reduce the presence of bacterial organisms by 99.999%,
killing MRSA organisms within 30 seconds. The normal standards require a killing
effect within five minutes.

http://Healthcare Enterprise Group PLC

and some more,

Healthcare Enterprise Group PLC
01 March 2004


Healthcare Enterprise Group Plc

Environment Protection Agency approval of Ebiox products

Healthcare Enterprise Group PLC (HCEG), the healthcare products and services
company, announces US Environment Protection Agency approval for a range of five
Ebiox decontamination products.

The products, Neozyme, Ultra P, Ultra L, RDA and SSC, are directed at the
surgical instrument cleaning market.

Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:

'This represents another achievement in opening up our marketplace for Ebiox.

' Yesterday we announced Laboratory results which confirm that Ebiox is highly
effective against bacterial contamination in hospitals. The laboratory results
together with this EPA approval will enable us to accelerate our marketing plan
for the products in the USA, the world's largest healthcare market.'

1st March 2004

http://www.uk-wire.com/cgi-bin/articles/200403010700139453V.html

keep an eye here http://www.uk-wire.com/

Healthcare Enterprise Group PLC
21 July 2004



Ebiox Handrub Successfully Completes EU Tests


Unique, EU compliant, Non-Alcohol Based Solution for Combating Hospital Acquired
Infections/MRSA

Healthcare Enterprise Group PLC ('HCEG') announces the conclusion of further
controlled tests carried out by the NHS Hospital Infection Research Laboratory
City Hospital, Birmingham on its Ebiox Handrub product. These results show that
the Ebiox Handrub is compliant with EN1500, the EU standard for continental
Europe and the UK.

EN1500 is the standard by which the efficacy of non-water based products is
tested under practical conditions. Ebiox Handrub exceeded the standards set by
EN1500 when tested against e-coli bacteria. The Handrub has previously passed
prEN12054 including efficacy against other bacteria including MRSA. These
earlier tests demonstrated a 99.999% reduction in all test organisms within 30
seconds, significantly exceeding the one-minute test target.

HCEG believes that the Ebiox Handrub is the first non-alcohol based product that
is compliant with EU standards and has been developed to be better than alcohol
as a hand hygiene solution. The Ebiox non-alcohol Handrub decontaminates hands
without drying or irritating the skin, and has been specifically designed to be
user-friendly to encourage more hand cleaning than the existing washing protocol
achieves.

The Department of Health has recognised that hand decontamination, before and
after patient contact, is 'vital' to the control of hospital-acquired
infections*. It has also identified that cleaning and disinfecting protocols are
key to 'reducing reservoirs of infection in hospitals'*. Current hand hygiene
protocols specify the use of alcohol-based products, but these can cause sore,
dry hands. As a result, hospital staff tend to be discouraged from adhering to
hand hygiene protocols. Statistics from the National Patient Safety Association
show only a 40% compliance with hand hygiene protocols, with the dislike of
using alcohol-based products being cited as one of the main reasons for this.
Furthermore some alcohol gels, which are formulated to reduce the drying effects
of alcohol, have been criticised for failing the EN1500 standard (Lancet, Volume
359).

The hand hygiene range at Ebiox will be marketed under the Esense brand by
leading distributor to the NHS, Vernon Carus.

Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:

'The EN 1500 test is significant because it proves that our Handrub is as
effective as alcohol, without the shortcomings of skin irritation associated
with alcohol based products.

'The Ebiox family of products are designed to improve hospital hygiene by
addressing the root of the hygiene problem, which is closely allied to working
practice. By developing a Handrub that hospital staff are more likely to use
frequently, we have taken a step closer to tackling the problem of hospital
acquired infections and the MRSA epidemic.

'It is clear that current products have not succeeded in this respect and so we
are calling on the NHS to fast-track the adoption of this next generation
product.'


21 July 2004


* See the Department of Health document - Winning Ways: Working together to
reduce Healthcare Associated Infection in England (
www.doh.gov.uk/cmo/hai/


should do the price a world of good

How about calling the TV news channels !

10 Million buy has just gone through!

Bid/offer now 1.80p v 1.82p

Up she goes again. Offer now 1.85p

Spread now 1.82p v 1.85p. Nice!

mrsa still on the news - NHS where are you?

At last some movement on some big trades

Duty Rumour from elsewhere.(A.D.F.V.N.)

has stated that the NHS procurement area have indicated that ebiox and its range of products was being purchased in ever increasing quantities by hospitals throughout the country.

STRESS ONLY A RUMOUR

how true no idea,but nothing wrong with adding a fuel to the fire.

Today the government annouces new standards in cleaniness for the NHS one of the reasons MRSA is spread is lack of handwashing by doctors when going from patient to patient. Good timing for this product.



http://www.bma.org.uk/ap.nsf/Content/PR%2DBMA+welcomes+key+target+on+MRSA+%2D+21+Jul+2004

I also think that these disposable endoscopes they have produced is going to be a big winner.
http://u.tv/newsroom/indepth.asp?pt=n&id=47111

Morning all. Nice to see we are blue again.

I love blue

Nice 2.5 million delayed trade has just shown up.

There seems to be no shortage of buyers this morning. Would expect to see another tick up soon.

HCEFF is Healthcare Enterprise Group Inc., listed on the Nasdaq Over The Counter (OTC) market.

It was formed in February 2001 as a result of a collaboration between London & Paific Healthcare Development, Inc. (LPHD) and Moore Clayton & Co, Inc. (MCCI).

LPHD is a life sciences private equity and advisory firm founded in November 1998 by its principals, Stuart Bruck and Michael Low.

MCCI is a financial advisory firm specialising in the financial services, media and communications and energy industries and was founded in 1999.

HCEFF was used to takeover Interactivity Group Plc. (a shell company with a UK AIM listing) ... due to the respective sizes of the two companies it was viewed by the LSE as a reverse takeover i.e. after the deal Interactivity Plc. owned the entire issued share capital of HCEFF.

Interactivity Plc. then changed it's name to Healthcare Enterprise Group Plc. (HCEG.)

In a nutshell, HCEFF had obtained a UK (AIM) listing for it's business ... quicker and cheaper than floating the business themselves.

HCEG Plc. is currently the holding company of the HCEGI healthcare development business, which provides strategic advice and associated services primarily to early stage companies operating in the healthcare sector in return for fees which are payable in cash, equity or equity related securities.

I doubt you'll ever see any announcements from HCEFF ... all their stock (shares) are owned by HCEG Plc. so will not be traded on the Nasdaq OTC market.

I've no doubt that retaining a US listing is a good thing ... one day HCEG Plc. may want a US listing and they will be able to do it quickly and cheaply (again) using HCEFF.

Good to see buyers taking advantage of that dip.

Buying is picking up again

Has anyone been contacted by a broker called Edward Tate & Co. The firm is not registered with FSA. Beware!

Alert from FSA concerning this company at:

http://www.fsa.gov.uk/enforcement/edward_tate_24june04.pdf

A nice 2 million buy has just shown up.

AGM scheduled for 11.00am on monday 26/july

Healthcare Enterprise Group PLC
23 July 2004



Healthcare Enterprise Group PLC


Increased shareholding in Ebiox Limited



Healthcare Enterprise Group PLC ('HCEG' or the 'Group'), the healthcare products
and services company, has acquired an approximate further 2% in Ebiox Limited ('
Ebiox') giving HCEG an effective majority holding of 51% of Ebiox, which owns a
range of proprietary cleansing and decontamination products for use in the
healthcare industry.



HCEG will pay 50,000 in cash and 35,000 in HCEG shares to Keith MacGregor, the
vendor, contingent upon the achievement of specific agreed 'milestones'. These
milestones relate to, amongst other things, the further testing of the product.



Furthermore, HCEG has granted four put options to the vendor to require HCEG to
purchase the remaining 49% of the share capital of Ebiox in four tranches
contingent upon the achievement of further agreed milestones. The consideration
payable upon exercise of each put option will be 250,000 to be satisfied in
cash, or by the issuance of HCEG shares, for each of the four tranches.



The vendor has also agreed to grant HCEG a call option to acquire the remaining
share capital of Ebiox so as to give HCEG an effective 100% of the share capital
of Ebiox. The consideration payable upon exercise of the call option will be up
to 1,000,000 to be satisfied in cash, or by the issuance of HCEG shares.



The put and call arrangements are in substitution for the option arrangements
entered into in February 2004 and announced at that time.



In the year end to 31 March 2003, the latest date for which accounts are
available, Ebiox made a loss of 51,161 on turnover of 57,643.



Stuart Bruck, Executive Chairman, Healthcare Enterprise Group PLC, commented:



'Ebiox products are already being used in 50 National Health Service hospitals
in the UK and has achieved a range of important milestones, which makes this an
attractive transaction for HCEG. Moreover, this new deal gives HCEG effective
control over the development of this exciting range of world class products. It
also provides for the outright acquisition of Ebiox once it has produced the
relevant results.'



23 July 2004

Enquiries:

Healthcare Enterprise Group 020 7351 7500
Stuart Bruck, Executive Chairman
Gordon Wood, Group Chief Operating Officer

College Hill 020 7457 2020
Nicholas Nelson
Corinna Dorward



Notes to Editors

Ebiox



Ebiox produces a range of patented cleansing, decontamination and disinfectant
products. The range includes hand hygiene products, hard surface cleaners,
disinfectants and products to clean and decontaminate surgical instruments.



The Ebiox antibacterial handwash and handrub are proven effective against MRSA,
E-coli and other important pathogens and are fully compliant with EU standards.
Uniquely, the products do not use alcohol, which has a drying effect and can be
a skin irritant.



The hard surface cleaners, particularly the TrionicPlus trigger spray and
Azowipe Active wipes are based on a lifting and removing concept, completely
removing biofilms and cleaning to molecular level. The product continues to be
active after use and cleans through oxidation action, not toxification which
means that there is no need to rotate disinfectants because there is no chance
of resistance developing (cf GMP guidelines).



Ebiox also offers a range of products for the effective cleaning of re-usable
instruments. Critically, these products remove all debris prior to the
sterilisation process thereby ensuring complete decontamination. They have
proven to be more effective than natural detergents and enzymatic detergents
currently available.



As well as the current range of products, Ebiox also has products for the
decontamination of dental aspiration lines and a veterinary product range,
EbioxVET.



Healthcare Enterprise Group PLC



HCEG is quoted on the UK AIM stock market with its head office in London and
subsidiary offices in Manchester, Liverpool, Cheshire, Germany and the USA.
HCEG is a business engaged in medical product distribution, occupational health,
first aid and medical consultancy markets. These businesses underpin a range of
innovative medical devices, which will be introduced to the market via HCEG's
own distribution network on an international basis.





This information is provided by RNS
The company news service from the London Stock Exchange

With MRSA in the news and the Government with egg all over its face, HCEG must be a good buy. The NHS just cannot afford to take no action. It must take steps to stop the spread of the MRSA virus. Any firm offering a solution is bound to prosper. Hold tight!

A nice 1 million buy has just gone through.

What is MRSA?
Staphylococcus aureus is a bacterium often found in 20-30% of the noses of normal healthy people and is also commonly found on people's skin. Most strains of this bacterium are sensitive to many antibiotics and infections can be effectively treated. Staphylococcus aureus which are resistant to an antibiotic called methicillin are referred to as methicillin-resistant Staphylococcus aureus or MRSA. Many commonly prescribed antibiotics are not effective against these bacteria. Some MRSA strains occur in epidemics, indicated by an 'E' before MRSA eg EMRSA-16, EMRSA-3 and may be distinguished from others by a number of special laboratory techniques.

How is spread of MRSA prevented?
Scrupulous handwashing by hospital staff before and after contact with patients and before any procedure, is the single most important infection control measure. It is most likely to prevent spread of MRSA from one patient to another, or from patient to member of staff who may subsequently pass the bacterium on to other patients. Patients with MRSA should be physically isolated in a single room with the door remaining closed and the room regularly damp dusted, or they should be nursed in a special ward away from other non-infected patients. The patient's notes should be clearly labelled 'MRSA' so that this type of accommodation is provided if and when they are admitted to hospital at any time in the future. It is important that the clinician looking after the patient in hospital notifies the general practitioner. If this has not already been done, then the patient or their family should mention to their general practitioner that they are carrying MRSA. This information should also be passed to any hospital to which the patient may be admitted in the future to ensure physical separation or isolation immediately on admission and hence reduce the possibility of spread to others. The use of antibiotics such as those applied inside the nose and bathing procedures previously described, will also help to reduce the risk of spread. Finally, when such a patient is discharged from hospital, their room should be comprehensively cleaned and all linen and other clinical waste disposed of in special bags.

A 5.2 million buy has just shown up!

Nice one

Buys v sells, 8.4 million v 4.4 million

USA approval read link for RNShttp://www.uk-wire.com/cgi-bin/articles/200407260700021800B.html

yep, more good news.

NS Number:1800B
Healthcare Enterprise Group PLC
26 July 2004


Healthcare Enterprise Group plc

Ebiox surface cleaning product passes tests required for US Environment
Protection Agency approval

Healthcare Enterprise Group PLC ("HCEG"), the healthcare products and services
company, announces that its Trionic Plus product from the Ebiox family of
products has passed tests required for US Environment Protection Agency (EPA).
EPA approval will allow the product to be offered to US hospitals and related
facilities and for industrial antimicrobial and other cleaning uses in the US.

Trionic Plus is a high power "terminal" disinfectant proven to be effective at
combating MRSA and other pathogens. HCEG believes that the product offers
significant safety advantages over all other commonly used disinfectants and
does not contain alcohol, chlorine or other irritating vapours.

Trionic Plus contains soil lifting agents and biocides, which allow removal of
soils and microbes down to the molecular level. It removes the invisible
surface biofilms, which are believed to provide a rich breeding ground for the
development of resistant bacteria.

For high-risk contaminated areas Trionic Plus provides a fast-kill solution for
bacteria on hygienic surfaces such as floors, walls, tables, beds and public
access areas. Unlike other commonly used surface cleaners, Trionic Plus works
by oxidation rather than toxification. This means that there is no need to
rotate disinfectants because there is no chance of bacterial resistance
developing.

HCEG is considering a range of US marketing and distribution options for Trionic
Plus, together with similar strategies for its surgical instrument cleaner
range, which received EPA approval in March.

Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:

"The US represents over half of the world's healthcare economy, with an annual
expenditure in excess of US$1.7 trillion and is a market with which we are
familiar. The sheer size of the market means entry into the US represents an
exciting opportunity for the Ebiox product range.

Since the US tends to lead in the adoption of new healthcare technologies, we
are confident that the obvious benefits these products have over existing
alcohol or bleach disinfectants will result in active product investigation and
assessment by US hospitals and other healthcare facilities."

26 July 2004

Nice opening this morning!

Monday blues.a great start to the week

Healthcare Enterprise Group PLC

AGM Statement


Stuart Bruck, Chairman of Healthcare Enterprise Group PLC ('HCEG'), the
healthcare products and services company, made the following statement at
today's Annual General Meeting:


'The start of the current year has seen continued progress with respect to
trading in our core products distribution business and further important
developments from Ebiox, Optiscope and our healthcare advisory business.


'Having completed the acquisition of First Aid UK in June, we are well advanced
with its integration into our existing healthcare products business. As part of
this process we have signed the lease for a 58,000 sq. ft. facility in
Warrington, which will enable us to consolidate our trading operation at one
facility in the UK, thereby achieving economies of scale and reductions in the
overall cost base. In addition, this will facilitate better cross selling of
product to the various customer groupings. We have also strengthened the
management team with the appointment of a Director of Marketing, a Director of
Sales, a new Managing Director for the SAFA-IPS business incorporating First Aid
UK and a Director of Operations to manage and integrate the combined businesses.


'The Company continue to explore additional acquisition opportunities in the
occupational healthcare and First Aid sector that would easily bolt on to the
existing platform.


'Significantly, given the widespread concern over the increase in Hospital
Acquired Infections and MRSA in particular, we continue to rollout the Ebiox
range of decontamination products with significant new product development.


'In an exciting development last week, we announced further test results for
Ebiox's hand hygiene products. NHS laboratory test results have now proven that
the handrub passes EU requirements. In these tests the Ebiox handrub has been
proven to reduce harmful bacteria within 30 seconds. We believe the Esense
handrub and handwash are the first non-alcohol hand hygiene products, which meet
EU standards and, as such, are truly the next-generation of hand cleaners. Not
only are these faster acting against MRSA than alcohol based products, but they
are also more user friendly, which should encourage better hand hygiene
practices in hospitals.


'Another significant announcement made last week related to our taking a
controlling stake in Ebiox Ltd. This will better enable us to make the kind of
investment in human and financial resources appropriate to develop this
important product platform.


'Earlier today we announced that the Ebiox surface cleaner, Trionic Plus has
passed tests required for EPA approval. EPA approval will allow the product to
be marketed in the US, the single largest market in the world for these
products. We are currently reviewing marketing and distribution possibilities
for the high power 'terminal' disinfectant. Trionic Plus oxidation rather than
toxification, which means that no resistant bacteria can develop and it's a
non-alcohol, non-chlorine product, unlike other commonly used disinfectants so
has significant safety advantages.


'In the fight against Hospital Acquired Infections, the NHS has been developing
a rapid review process as part of its 'Winning Ways' strategy. We have called
on the NHS to go one step further in the fight against Hospital Acquired
Infections by adopting next-generation products such as the Ebiox range.
Indeed, we are actively campaigning for a revision of NHS protocols in this
respect and we intend to hold an R & D event in September to explore these
issues further.


'Ebiox is just one of a number of new technologies being introduced by
Healthcare Enterprise Group. A parallel focus for us is Optiscope Technologies
Ltd a proprietary disposable rigid endoscope developer. Earlier this month we
announced the acquisition of a controlling interest in this company. Since it is
patented we believe Optiscope is the only disposable endoscope being developed,
with significant cost and hygiene advantages. We aim to launch Optiscope
towards the end of next year and are already in early stage discussions with
parties interested in licensing or distributing the product.


'To round out the picture, our healthcare advisory business, headquartered in
the US, is assisting the Company with the vital market research services
required to roll out our products internationally, as well as providing a
growing quantity of fee-based services to companies not competitive with HCEG.


'Taking all of this into consideration, I believe that HCEG is in excellent
shape and well positioned for the coming year. The directors look forward to
the year with optimism.'


26 July 2004


Enquiries:

Healthcare Enterprise Group PLC Tel: 020 7351 7500

Stuart Bruck, Executive Chairman

Gordon Wood, Chief Operating Officer

College Hill Tel: 020 7457 2020

Nicholas Nelson / Corinna Dorward


This information is provided by RNS
The company news service from the London Stock Exchange

Not a good start today. Why?

This was posted on AFX yesterday, I'd say its positive. I'm ignoring the dip this am;


Healthcare Enterprise optimistic about FY; seeks acquisitions ( )
LONDON (AFX) - Healthcare Enterprise Group PLC said it is optimistic about

the current year after seeing continued progress in its core product distribution unit and important developments in other businesses.
The company also said it continues to explore acquisition opportunities in the occupational healthcare and first aid sectors.

What is the difference between HCEG and HCEW, does anyone know. Is this the warrant price.

This morning RNS announcement:

LPMCC, a major shareholder, granted 110,392, 544 options over shares and warrants to 4 directors.
LPMCC is owned by Stuart Brook (EC) and Michael Low (CEO) and owns 22% of HCEG.
Stuart Brook owns 80%, Michael Low 20% of London Pacific Development (LLC) which which owns 96.5% LPMCC.
Could this be the reason for the drop in price today?

Hotrott, You are correct in your assumption, HCEW does indeed relate to the warrant price.

Angi, I feel it probably has more to do with the predicted time scale of forthcoming events, i.e. punters who were after the quick return jumping ship, still a good long term punt imho.

I thought HCEW was thanks for the confirmation Loadsadosh.

A big 10,000,000 buy this afternoon !!

Interesting article on the BBC News website. A watchdog (the National Patient SafetyAgency) has recommended that hospitals provide hand gel beside patients beds to encourage staff to wash their hands in an effort to beat MRSA. This looks like a good opportunity for HCEG to get sales of Ebiox rolling.

See the full article here:
http://news.bbc.co.uk/1/hi/health/3614058.stm

Anounced on the TV news today, following a trial in several hospitals with good results, the hand gel bottle will be placed at the bed of each patient to be used by Doctors and nurses. This scheme will be rolled out nationwide and is expected to reduce deaths by 450 a year. I hope!!- I hope they are using the gel made by HCEG but why isn't the company announcing any trading update?

I have read elsewhere that the NPSA are evaluating EBIOX along with the data supplied by HCEG next week.

http://81.144.177.110/display?contentId=3258

the link is for the NPSA website where we can keep upto date with their (NPSA) offerings.

Pleased to see this stock moving north

Interesting article here

News-Medical.Net MRSA bugs immunity to hospital disinfectants and antiseptic

Posted By: News-Medical in Medical Patent News
Published: Wednesday, 8-Sep-2004



Dangerous multi-drug-resistant bacteria are also developing immunity to hospital disinfectants and antiseptics, according to new research presented today at the Society for General Microbiologys 155th Meeting at Trinity College Dublin.
Some of the most worrying microbes around, the drug-resistant bacteria known as MRSA (methicillin-resistant Staphylococcus aureus) have been discovered in heavily disinfected hospital locations such as catheters and on the disinfectant soap dispensers used in wards.



http://www.news-medical.net/?id=4581

Todays Shares Magazine has an article "Superbug Blitz".
Very dissapointing that HCEG nor Ebiox do not get a mention.

some big share trades today upto 45,000,000 so far

extract from Hansard today.

Mr. Lansley: I must remind the Secretary of State that the motion refers to many other ways in which failings in action have been laid bare by the NAO report. I will not be able to detail them all, but I want to ensure that the House is aware of them.

8 Sept 2004 : Column 790

"In a debate in July, my right hon. Friend the Member for Hitchin and Harpenden (Mr. Lilley) made specific reference to several new products and processes that have been offered to the NHS. He is not able to vouch for their effectivenessnor am Ibut that is why a rapid review process should be established. Ebiox is a non-alcohol cleansing product."

At long last things maybe beginning to happen.

http://www.publications.parliament.uk/pa/cm200304/cmhansrd/cm040908/debtext/40908-23.htm

Puzzled by the Shares article which mentions neither HCEG nor Bioquell (BQE). I suspect it is an article written by a journalist asked to do some brief research who has picked up just part of the story. Though I would check through this bb for enlightenment but may be just more confused. Can anyone give an objective view of (a) the relative merits of the different technologies attemting to tackle MRSA; (b) the timescale on profitability of the companies involved? I looked at HCEG when written up as a "penny share" in Shares, which was somewhat ludicrous when there are 2.9 billion of them (why so many?). The cap. of HCEG and Bioquell is broadly similar: HCEG have bought rights to EBIOX and it appears on-going research from the inventor; Bioquell have developed their own technology. The former appears to be primarily a marketing company, the latter a technology company. Bioquell's recent announcements concern academic research and two successful projects in French hospitals. Any insights?
Eric

Eric all info here.

http://www.advfn.com/cmn/fbb/thread.php3?id=6399024&from=1

Bioquell totally different product and believe they in effect steam clean rooms.They have also only cleaned a couple.The MRSA bug is carried thru the air,and 99% of us carry it to varying degrees,therefore hitting the source is the more important and that is where HCEG have a distinct advantage.

Below is a write up by citywire a while ago.
Citywire article
----------------
Bugs beware: Healthcare Enterprise is after you
Published: 09:42 Thr 26 Feb 2004
By Algernon Craig Hall, Secret Buying Correspondent

Big news for Healthcare Enterprise Group; the NHS has found its Ebiox product to be an effective solution for eradicating bacteria including the MRSA 'superbug'.

Testing has found Ebiox to be incredibly efficient at removing then destroying bacteria from two key areas hands and bacteria-laden work surfaces and floors.

The cleaning process using Ebiox also works in 30 seconds compared with normal standards which require a killing effect within five minutes.

Ebiox can now start to be used in hospitals which could lead to big orders. There is growing concern about the spread of disease inside hospitals, especially the so call superbug, and effective and quick decontamination has the potential to be very effective in tackling the problem.

Ebiox is one of a number of exciting projects that Healthcare has invested in. The company also makes and distributes occupational healthcare products such as Ebiox's decontaminants and first aid kits and is aiming to act as a consolidator in this fragmented sector. In addition it runs a related consultancy business which has a good US presence and is looking to expand in the UK.

Hope of some use.

Rumour of the day



Healthcare Enterprise, the AIM-listed medical products group, held steady at 1.89p, despite murmurs that it is set to disclose details of a new application for Ebiox in the US on or before its first-half results early next month. The Ebiox range comprises disinfectants used to combat hospital-acquired infections

http://www.timesonline.co.uk/newspaper/0,,2727-1308426,00.html

Quite interesting Ebiox should have an application in the US. Last week, on the Scottish news, the hospitals were discussing using a hand disinfectant sourced from the US - felt like ringing them up and suggesting they consider home grown product!! The US product looked to be serving exactly the same role as I understand Ebiox does.

If it's in The Times it must be correct. now upto 1.92p on bid

On the 9th Nov it'll be 2 months since the director dealings, perhaps then we'll have some long awaited news or confirmation of the 'the rumour'. Results are due too.

skids

Are results due soon-anybody know?? Another share that has never heard of good PR !!

Intrims were end of November last year so I assume similar for this year.

I think its worth buying for interim results in november & all the talk of MRSA superbug in news each day maybe some good news in pipeline?

The NHS will not be buying this Ebiox stuff until such time as it is shown to be better than the rival products. We know it meets all the Standards, but so does everything else (or they could not be sold on the market). If it's just the same people will not buy it unless it's cheaper. If it's better and so worth paying more for, you'd have thought there'd be some actual scientific clinically relevant evidence to prove it. There isn't. So no sales. Period.

$10 million dollar contract for the use of Ebiox in the USA


http://tinyurl.com/567hn

excellent news and bid moving up rapid.

numis morning meeting 8, nov. healthcare enterprises (1.86p) BUY target price 2.40p -us deal

This is a major deal and the implications of this deal are huge.IMHO this is just the start and based on this deal alone, SP will move up very fast.
Do your research and act before it is late. I hold shares in this company.

I think this is the best news for ages in this company, bought in this morning.
opto

Ticking up again this morning

see the bid went up to 2.0p following the announcement this morning ref Optiscope thought would post it incase anyone missed it.

Healthcare Enterprise Group PLC
10 November 2004


Healthcare Enterprise Group PLC

Optiscope Technologies Ltd Manufacturing Agreement

Optiscope time to market, accelerated through agreement with Wahl Optoparts


Healthcare Enterprise Group announces agreement with Wahl Optoparts GmbH, a
division of JENOPTIKS AG, for the development and manufacture of Optiscope, a
rigid endoscope based on proprietary technology. Optiscope is one of HCEG's key
portfolio technologies. JENOPTIKS AG is a world leader in photonics
technologies operating out of twenty countries with group sales of 3 billion.

Optiscope combines a revolutionary, patented optical design with innovative
plastic manufacturing methods and components, to produce a disposable clinical
product with no compromise to functionality. This gives Optiscope a significant
clinical advantage by removing the risk of cross contamination normally
associated with the re-use of expensive endoscopy equipment. Optiscope's
products will have high quality optics and are planned to be marketed at an
extremely attractive unit cost to hospitals, clinics and general practitioners.
In addition to the elimination of cross contamination, the low price will enable
bulk purchase, thereby streamlining procedures and reducing waiting times.

As part of this agreement, Wahl Optoparts has undertaken to perform a series of
laboratory tests on Optiscope's optic design and plans to introduce, together
with Optiscope, additional elements of its own expertise that will enhance both
the intellectual property and product functionality. It is thought that the
partnership with Wahl Optoparts will accelerate time to market for the finished
product by nearly a year. HCEG now anticipates that a commercial product will
be available for FDA inspection by mid 2005.

Optiscope is uniquely competitive in the endoscope market. The cost of a
comparable re-useable rigid endoscope is circa $3,000 per instrument. These are
frequently damaged during use, resulting in costly repairs. They also require
disinfection, decontamination, sterilisation and servicing following each
operation and, with a life span of approximately 200 operations, the estimated
cost per use is $40.

Gabriele Wahl-Multerer CEO, Wahl Optoparts GmbH, commented:

'The relationship with Optiscope provides Wahl Optoparts with an exciting
opportunity to develop our business in optical products and demonstrates our
commitment, as an OEM supplier with a closed process chain, to the international
medical market.

'Wahl's know-how and established procedures will ensure effective development
and manufacture, for example, through giving us 100% traceability throughout the
total production process. We are extremely excited to be associated with
Optiscope.'


Stuart Bruck, Executive Chairman, Healthcare Enterprise Group, commented:

'This relationship with Wahl represents a pivotal step for Optiscope and sets
out the timetable to market. Wahl, as part of the mighty JENOPTIKS, should be
viewed as major endorsement and confirms our original belief, that Optiscope has
significant market potential.

'Both Ebiox and Optiscope have received acclaim at the highest levels which will
provide HCEG shareholders with confidence in management's ability as we move to
roll out our new product portfolio.'

10 November 2004


Enquiries:

Healthcare Enterprise Group PLC 020 7351 7500
Stuart Bruck, Executive Chairman

College Hill 020 7457 2020
Nicholas Nelson/ Corinna Dorward

November 11, 2004

Smaller stock to watch



Healthcare Enterprise, the AIM-listed medical devices specialist, edged up 0.03p to 1.99p on signing a manufacturing agreement with Jenoptiks, a German company with 3 billion (2 billion) of sales. Jenoptiks will develop and make Optiscope, Healthcares disposable endoscope, which is expected to be ready for inspection by the US Food and Drug Administration by mid-2005. Numis Securities yesterday repeated its 2.4p target.

http://www.timesonline.co.uk/newspaper/0,,2727-1353271,00.html

Up again today--at last we are seeing some good results. Any trading figures due soon?

Good news about the acquisition of Crest Medical today and interim results will be out today at some point

No sooner said than out. Link to interims

http://tinyurl.com/3kxgv

Good results good prospects but I am out because any company share consolidation usually seems to cause a drop in price after consolidation--look at Icap, Majestic wine and planestation for example. I look to buy again when things have settled down

Yes, it's certainly dropped in price recently!!! :-) Massive potential market in USA which they seem to be tapping into well enough. Must reap benefits mid to long term if the sales and marketing departments are so active and successful?

Up again! Anyone get out of these recently? OUCH!!!!!

Fidelity bought over 3% according to RNS this morning,also the bid rose and the spread came in,are there further buys in the offing and can we expect another RNS any idea's?.

Looking very strong this AM only three trades recorded as sells. Spread went down as low as .459% earlier. No news about but looks interesting

LONDON (AFX) - Two products from Bioquell PLC and Healthcare Enterprise Group PLC have been identified by the UK Department of Health's Rapid Review Panel (RRP) as having potential value in the battle against the MRSA superbug in hospitals.

The panel highlighted Bioquell's RBDS de-contamination system, which use a range of hydrogen peroxide vapour systems to de-contaminate hospital rooms, and Healthcare Enterprise's Ebiox range of hand hygiene products that use non-alcohol based gel for hand cleaning.

However, the panel concluded that the products still need to be subject to further evaluation in an NHS clinical setting.

Bioquell said the results of the trials are encouraging and its will be working with the RRP to agree the basis on which it should supply additional data, which would allow its technology to be introduced into NHS clinical practice following peer reviewed trials and economic appraisal.

Nick Adams, chief executive of Bioquell said: "The positive recommendations of the RRP should make it significantly easier for us to sell our unique technology to eradicate MRSA and other "superbugs" in hospitals in the UK and internationally."

Commenting on the Bioquell product, the panel said: "The product has been shown to be effective in removing MRSA from the hospital environment. Results suggest that Bioquell hydrogen peroxide vapour is most effective on non-porous surfaces.

(The product) is only appropriate for enclosed rooms and units that can be emptied of patients and staff and sealed for the period of decontamination.

The key question is whether the ability of Bioquell hydrogen peroxide to kill environmental micro-organisms will translate into reduced numbers of healthcare associated infections."

The Rapid Review panel is made up of top UK scientists, and was set-up by the Health Protection Agency at the request of the Department of Health to provide a prompt assessment of new equipment, materials and other products or protocols that may be of value to the NHS in improving hospital cleanliness, hygiene and infection control.

Proposals received or identified by the Department of Health are referred to the panel for review.

The panel does not conduct evaluations of products but reviews information and evidence provided and makes recommendations to the Department of Health.

Healthcare Enterprise Group PLC
01 December 2004


Healthcare Enterprise Group PLC


Ebiox Handrub


Health Protection Agency review confirms effectiveness against Hospital Acquired
Infections


Healthcare Enterprise Group PLC is pleased to report a satisfactory outcome from
the Rapid Review panel of the Health Protection Agency, following tests at the
Hospital Infection Research Laboratory, showing that the Ebiox Handrub conforms
to EN 1500.


EN1500 is the standard by which the efficacy of non-water based products is
tested under practical conditions. In tests earlier this year Ebiox Handrub
exceeded the standards set by EN1500 when tested against e-coli bacteria. The
Handrub has previously passed prEN12054 including efficacy against other
bacteria including MRSA. These earlier tests demonstrated a 99.999% reduction
in all test organisms within 30 seconds, significantly exceeding the one-minute
test target.


HCEG believes that the Ebiox Handrub is the first non-alcohol based product that
is compliant with EU standards and has been developed to be better than alcohol
as a hand hygiene solution. The Ebiox non-alcohol Handrub decontaminates hands
without drying or irritating the skin, and has been specifically designed to be
user-friendly to encourage more hand cleaning than the existing washing protocol
achieves.


An independent survey by Nursix has shown that two thirds of nurses reported
skin problems using alcohol based products and that they would be more compliant
with NHS protocols if a non-alcohol based product were available.


The Rapid Review Panel has concluded that Ebiox hand disinfectant; 'may have
potential value as an alternative to alcohol-based gels for hand hygiene: in use
evaluations/trials are now needed in an NHS clinical setting to show
acceptability in routine use'.


Stuart Bruck, Executive Chairman, Healthcare Enterprise Group, commented:


'These tests now provide a stamp of approval from the Government taking us to
the next step in our bid to tackle the Hospital Acquired Infections epidemic.


'We will be guided by the Rapid Review Panel which recommends on the ground
tests in an NHS setting.'


The Rapid Review Panel was set up by the Health Protection Agency in August 2004
in response to the Chief Medical Officer's Action Area 7 in Winning Ways.


The remit of the Panel is to promptly assess new procedures and products with
regard to their potential effectiveness and ability to prevent, reduce or
control healthcare associated infections (HCAI).



The key element of acceptability is the demonstration of a significant effect on
HCAI in the clinical setting. Ideally, this will be the result of formal
clinical studies reported in peer-reviewed publications.

1 December 2004


Healthcare Enterprise Group PLC 020 7351 7500
Stuart Bruck, Executive Chairman

College Hill 020 7457 2020
Nicholas Nelson/Corinna Dorward

YOU'VE JUST GOT TO BE HAPPY WITH THIS NEWS!!!!!

And I know HCEG's management and sales team will be moving into overdrive to sell this product on the back of this news.

Anything that gets passed so quickly through any governmental system has to be pretty bloody good as a product and something that can be used for political means as well.

Now the goverment can take credit for "discovering" and approving this product. Future blame can be placed fair and square on the NHS hospital managers should they choose not to buy it in!

BIG, BIG, BIG sales ahead IMHO, DYOR, etc, but this company is really going places with ebiox based products!

Telegraph today report Health Minister John Reid's speech in which he identified eibox as the right stuff.Good news again but sp not moved up much. Probably the 25 for 1 consolidation is holding it back.A lot of people will wait until the sp steadies at 50p or whatever.

bid could be held back to allow further institutions to get on board at a set price and drop in an occasional large sell and it keeps the price remaining even without going beserk.

Believe this was a no brainer bearing in mind HCEG products have passed everyone else's tests (check all previous RNS's)

Note EU handrub tests back in July 2004http://www.uk-wire.com/cgi-bin/index?search_type=3&words=hceg&go.x=22&go.y=14

This continues to climb at a steady rate. reaching the kind of levels it did previously befor its retracement. Needs to find support as it has done and this could and should go onto great things. No idea on what price it could climb to but 5p must be a target within a 3month period? Afer that.....hold on. It goes without saying DYOR.

Although a holder I'm not impressed by management...the AGM was a real let-down like the School Govenors were talking to an intake of first-year pupils. That was some time ago and we have seen very little product activity - if you had such a wonderful product, why wouldn't it be in the public arena in record time?
(ignore the NHS route, just flog it through Boots/ASDA)
/
What we are left with is a company with millions of shares (soon to be consolidated 25:1 ) which have not shifted much product and whose sp is within a wisker of what it was when the Good News was first thrown to eager investors.
//
On MRSA itself, I can claim no Authority, but FWIW if we all carry the seeds of MRSA then cleaning a ward will not help - the MRSA will return with the first humans to enter. Until you can breed cloned-sterile medics, hospitals need another way to combat MRSA. I think the "hand-washing" is a smoke-screen and it's being played out to keep the Public from panicing. - - -Once installed - - - we can watch the MRSA fall to zero -(I don't believe it!)
//
Isn't it like blocking up the keyhole (of a door) to guard against nuclear fallout (dust) when the windows are open? The promise of a cure (by getting staff to wash their hands every few minutes ), seems a little unrealistic....you'd need a 30% increase in staff to keep changing the bottles and make-up the nursing-time lost, etc.

Don't you just get the feeling that MRSA is not about to be cracked, yet?

I am not convinced HCEG will make me a profit, either.

there is more to HCEG than Ebiox.

hangon, if your views on the use of Ebiox were applied to other hospital cleaning agents that are presently in use. Death through contamination would be rampant. Any product that reduces the presence of germs in such confined areas, at temperatures that encourage bacterial growth, must surely be used.
Do ask your self a question. If you were given the choice of recuperating in a ward cleansed by Ebiox or in one that had not been, which would you choose?

Hangon why don't you check things out prior to writing below is the link to the interims on 17th Nov 2004 and look it says they made a small profit.

You may not of made a profit but they have.


Healthcare Enterprise Group PLC
17 November 2004

Healthcare Enterprise Group PLC

Interim Results for the six months ended 31 August 2004

Acquisition of Crest Medical From Unichem Ltd - A Division of Alliance
Unichem plc

Interim results for the international healthcare company focused on specialised,
high-value products, supply and services in the UK, Europe and the US.

Key points

Maiden profit of 0.3 million profit after interest, tax and
exceptionals, on turnover of 5.6 million following the company's expansion
into UK occupational health and first aid sub-sector where it now has a
leadership position



http://www.uk-wire.com/cgi-bin/articles/200411170746233212F.html

This reads like good news to me. Does this mean that if I own say 100,000 shares at the moment I will get 4000 extra shares issued to me worth 2.5p which I am free to sell straight away and my existing shares will still be worth exactly what they are. I know this is all going to seem so obvious to someone but I just need to fully understand this 100%. Thanks for input and any clarification.



Extraordinary General Meeting - Proposed Ordinary Share Capital Consolidation

The Board of HCEG is pleased to announce proposals to consolidate the Company's
ordinary share capital on the basis that for every 25 existing ordinary shares
with a nominal value of 0.1 pence each owned by a shareholder on the record date
(being 6 p.m. on 10 January 2005), they will receive 1 new ordinary share with a
nominal value of 2.5 pence.

Edit

i am a little confused i thought it meant for every 25 shares owned it would be replaced by 1 meaning a holding of say 100,000 would give you 4000 shares in their place thats what happened with MXC ....if someone could clarify for me please
this is what i have
The process by which a company changes the structure of its share capital by reducing the number of shares it has in issue and increasing the par value of each. For instance, a company with 100,000,000 shares in issue having a nominal value of 10p might consolidate on a 1-for-10 basis, reducing the number of shares to 10,000,000 and changing the nominal value to 1. As a shareholder, the number of shares you own would be reduced, their nominal value would rise to compensate, and the market price of the shares should also rise to reflect the greater 'ownership' which each share represents in the company.
In the case of MXC the share price jumped from 10p to about 1.50 but your holdings were reduced all round it still meant a profit
Note that a consolidation is the opposite of a scrip issue, in which the number of shares rises, and their nominal value and market price falls

I notice that several buy trades for 250,000 shares have gone through, two of them broker to broker. That reads to me that some of the brokers are not carrying stock. Now that could be interesting if the buying really hots up :-))

Spread down to 0.82% now that's tight!!

Zul187 your right it's 1 share for every 25 owned all it will do is make the shares more attractive to others who ordinarily would not buy stock at such a price, after consolodation these will rise will rise.

RobRocket
Afraid it isn't as nice as that. It's a 25 for 1 consolidation - which means 100000 becomes 4000 at whatever the price adjusts to become. At today's spread that would be 60.5/61.25.

I've made a bit on these in the past but will not chase these prior to consolidation. All those I've been in before seem to pull back after the consolidation - so will look to try and get back in around 50p - or current price 2.00p

Good luck to those who are sailing in her.

Just one sell trade so far this AM. Spread down to 0.402% MM's wanting to trade and looking for stock I think.

Continues to climb well, seems to be no stopping this baby at the moment. Long may this continue. Thanks for all the comments earlier on this thread, much appreciated guidance. Lets see where this one is heading: Blue Sky hopefully.

I've sold. Good luck all.

Early Simon? I think there is much more upside here. But if you have made the profit you want, that's what it is all about.

No intention to deramp this stock because I think it's a great story. However, I just hope people are aware of the implications of consolidations. My own experience is that they have invariably led to pull backs after the new price is posted. As I said earlier up the thread I will be watching them closely to see if I can get in on any pullback.

Might be completely wrong - if so then que sera - but at least I will feel as if I've stated my fears - and proved to be incorrect. Otherwise they would be a screaming buy on any fall back to about 2p/50p. Current post-consolidation price will be 60/66p.

Good Luck

long way to go before the 10th so could climb a little further before then,if you think a retracement likely following that date I'm sure in the longer term they will soon recover.

Upanddown - have you got a target price in mind? Cause again today its going strong. I Think its up about 20% this week alone!!

0.24p gain so far today, that's some rise!! Looking at the chart I would not be surprised to see these step back a little soon, unless good news on Ebiox is released shortly.

RobRocket these could go anywhere judging by what seems panic buying as I prefer a slow rise,now at 2.8p bid, weekend press comment could push further but as for targets I depart when I feel comfortable and at the moment, not at this stage.

Please watch out for yourselves as no-one else will

You have to look back as far as January '02 for prices this high. There was a peak of 2.35 then which will provide some resistance on the upside. A break of that, though, could take us all the way to 4p.

On the downside, the 2.4p level should provide support as it has taken the best part of 3 years to break above it again.

My current view, though, is that this is driven much more by fundamentals than technicals at the moment. The forecast is that HCEG will break into a modest profit (0.05p/share) in 2005, doubling in '06.

dclinton,don't know where you gleaned that info as prior to Nov 2003 it wasn't trading perhaps your getting mixed up with an old software company that used the name prior.As I believe HCEG was ressurected from a shell company.

Then again I may be wrong.

From http://www.armshare.com/index.php

updandown - the armshare site MarketData link for HCEG takes me to http://uk.finance.digitallook.com/cgi-bin/digital/security.cgi?ticker=hceg which shows year ends all the way back to 2001.

The data I'm working with comes from ShareScope which shows prices back to May 3rd 2000. It may well have been a shell up to Nov 2003, which would correspond to a sudden increase in trading volume at that point. From a purely chartist point of view, though, I don't think that's relevant, though as I said I think fundamentals are currently driving this more than technicals. It's still nice to have historic support levels.

Looks like we're getting a bit of consolidation today which is good. A few days of that will provide a nice support level for any further gains.

Buy 5000
Sells 1,263,099
If those are correctly reported trades surprised the SP has not dissapeared into the ground today!
Is the lack of support due to the dearth of news on Ebiox perhaps.

if no-one was mopping up the price would plummet either someone is or there is news on the horizon and someone (mm's) maybe saving up!.

The thing about market-maker controlled shares is that buys/sells don't always cause the expected response in the price. Looking at those figures, the market makers have just taken posession of over a million shares in what is quite a strong company. They are unlikely to drop the price and sell them back out to the market at a loss, are they? Instead, it seems to me more likely that they will put the price up. The market will then percieve strength and buy them back at a higher price than the MM's paid for them.

This is all very different to the SETS trading where individuals are selling directly to each other.

Doug

I assume the approaching consolidation of HCGE on the 10/01/05
i.e 25 to 1 share @ 2.50p means that the price of this share will drop to 2.50p
on or prior the 11th Jan 2005 or have I got it wrong ?

mc mahon...what it means in real terms mate, is that for every 25 shares you own, you will in future only own one, however it will be worth 25 times as much...eg if you own 50000 shares at 2.68 p the closing night before consolidation your holding they will be worth 1340 pounds...on the morning of the consolidation you will then own 2000 shares @ 67p ( which is 25 X 2.68p), which is worth 1340.

So in real terms no win or lose...the only benefit is to HCEG who will therefore have to manage far less shares as they are of higher value. However that must be good for us in the long term as cost savings to HCEG benefits us shareholders.
Also you mustnt lose sight of the fact that we have an odd perception that a company whos shares are 67p are likely to be much more professional and successful...strange but true

sit tight for 2005 and we will most probably reap the beenfits of this company who really seeem to be going places...have a good one mate...pb

cheers

I wonder if anyone can remember any company that played with its share-structure, that subsequently benefited the retail shareholders (ie us punters) maybe over two years before the consolidation, to two years afterwards?

It seems to me to be an act of desperation, to try and get some life into any sp.

As to reducing cost for the company I don't see it - they still have to have audits, send out accounts and hold AGM's - apart from some tiny holdings that are swallowed up (sometimes cashed) the only effect is a perceptional one (as others here have said) -and for that one has to wonder why the shares were so lowly-priced before, or was this a wheeze to give their Brokers an extra job?

HCEG does have Ebiox but it is not true it's the only answer to MRSA, there are competing products from large companies although there are two fundamental problems to overcome //IMHO:-
1) getting everyone in hospitals to use it
2) not letting the superbug grow resistant to our efforts.

I understand the iodine wash (used before Ops) would kill MRSA, except it leaves you looking orange(if applied on Wards). TV Reports of people who have contracted MRSA after Ops seem to have it "internally" perhaps because their natural defenses are suppressed. The MRSA bug is said to originally reside in our noses (without doing harm)- so the whole process is not just hand-washes. Let's hope they send out fresh Certificates so we don't get the problems of selling many that we don't own.

If HCEG has made a profit it will be quite small as their turnover is low compared with capitalisation (prior to buying a distribution company) and shareholders will pay for the many Director Options. Profit is only any good when it is distributed to shareholders - then we can see the return against the risks.

I have sold and moved on as I have had burnt fingers before. eg. Baltimore--I used to own 4500 valued around 8000 I now own 3 !! after two consolidations, just another word for robbery!

Decided to hedge my bets and have sold half my holdings. Sitting on a 30% profit at the moment so may as well free up some money to put elsewhere.

Some while ago it was announced that Ebiox had been sent to the governments Rapid Response Panel for evaluation. Now we know that the governments interpretation of rapid could be slighty different to ours, but it is some while ago and the 'bug' is still about, although publicity about it has waned recently. Must be time soon for the panel to release its results. Unless I have missed the report then I would appreciate being informed of the outcome.
opto

Hi Opto
I seem to recall an article stating that Ebiox had passed the required NHS tests, I will try to trace and post the article.

Opto
Took less time than I thought I would be interested on your evaluation of the intended consolidation with respect to a hold or sell situation.


Healthcare Enterprise Group PLC
01 December 2004


Healthcare Enterprise Group PLC


Ebiox Handrub


Health Protection Agency review confirms effectiveness against Hospital Acquired
Infections


Healthcare Enterprise Group PLC is pleased to report a satisfactory outcome from
the Rapid Review panel of the Health Protection Agency, following tests at the
Hospital Infection Research Laboratory, showing that the Ebiox Handrub conforms
to EN 1500.


EN1500 is the standard by which the efficacy of non-water based products is
tested under practical conditions. In tests earlier this year Ebiox Handrub
exceeded the standards set by EN1500 when tested against e-coli bacteria. The
Handrub has previously passed prEN12054 including efficacy against other
bacteria including MRSA. These earlier tests demonstrated a 99.999% reduction
in all test organisms within 30 seconds, significantly exceeding the one-minute
test target.


HCEG believes that the Ebiox Handrub is the first non-alcohol based product that
is compliant with EU standards and has been developed to be better than alcohol
as a hand hygiene solution. The Ebiox non-alcohol Handrub decontaminates hands
without drying or irritating the skin, and has been specifically designed to be
user-friendly to encourage more hand cleaning than the existing washing protocol
achieves.


An independent survey by Nursix has shown that two thirds of nurses reported
skin problems using alcohol based products and that they would be more compliant
with NHS protocols if a non-alcohol based product were available.


The Rapid Review Panel has concluded that Ebiox hand disinfectant; "may have
potential value as an alternative to alcohol-based gels for hand hygiene: in use
evaluations/trials are now needed in an NHS clinical setting to show
acceptability in routine use".


Stuart Bruck, Executive Chairman, Healthcare Enterprise Group, commented:


"These tests now provide a stamp of approval from the Government taking us to
the next step in our bid to tackle the Hospital Acquired Infections epidemic.


"We will be guided by the Rapid Review Panel which recommends on the ground
tests in an NHS setting."


The Rapid Review Panel was set up by the Health Protection Agency in August 2004
in response to the Chief Medical Officer's Action Area 7 in Winning Ways.


The remit of the Panel is to promptly assess new procedures and products with
regard to their potential effectiveness and ability to prevent, reduce or
control healthcare associated infections (HCAI).



The key element of acceptability is the demonstration of a significant effect on
HCAI in the clinical setting. Ideally, this will be the result of formal
clinical studies reported in peer-reviewed publications.

1 December 2004


Healthcare Enterprise Group PLC 020 7351 7500
Stuart Bruck, Executive Chairman

College Hill 020 7457 2020
Nicholas Nelson/Corinna Dorward

Thank you Loadsadosh, So it appears that we will just have to be patient for a little longer.
About the consolidation, I do not have fond memories of previous companies I have been involved in that have consolidated i.e. Costain, Planestation and Cybit (only recent so we don't know how this will go yet) but the other two have been costly!! However as regards HCEG I am not in selling mode as I do think that this product if it gets taken up with enough authorities would send HCEG into a different league. As you are no doubt aware one American State has began using it, good results from there would open up a vast market..........
The World!
opto

Opto
It would be great if the company were to have a positive statement up their sleeve in order to offset any negativity following the consolidation. I must confess, if it were my company and I had good news, I would hold it for just that eventuality.

well todays the day and expect great activity which will bode well for the share price.consolodation looking around 68/69p and follow consolodation maybe the end of it being a penny share is in site.I believe anything under a 1 is classed as a pennyshare.

Over 1m sells so far this morning and no sells - price holding.

Looks as if I might be able to get some @ my 50p target (2p in old money).

Always seems to be the case after a consolidation - from bitter experience.

Active this AM more than half a milliom shares traded by 8.07

Looking good

3.8 million shares traded now, mostly recorded as sells! now that surely can't be the true picture or they should be down as much as they are up.
As it is nice volume price rising....good sign!!

bid up at 74p some huge buys late on yesterday obviously MM's desperate to buy does that mean large buyers in the background?,

It's not just Ebiox which promises so much,I'm also interested in the range of disposable endoscopes produced by Optiscope Technologies,in which HCEG has increased its holding to 66.25%A first run of 1000 prototypes will be clinically tested within two months.This is almost as interesting as Ebiox.No more cold metal objects ......etc.In today's filthy hospitals everything should be sterilised and disposable.I bought some yesterday...gone rigid today...what should the price be that I can hope for?Shares,not endoscopes,that is.Ethel

Nice to see this one keeps making new highs.

six days and no one has answered my question..is anyone out there a buyer,like me??This has GOT to ROCKET:..

I'm a holder. I don't have a target. This is simply an excellent company with superb growth potential which has already almost doubled the money I put into it. I expect a lot more over the next couple of years.

doug

OK ethel, you and Doug are not on your own, I'm a holder. Not been in very long but showing a small gain. Soon as Ebiox gets accepted by our NHS who at the present time appear not to be rushing around about MRSA then HCEG must move into a different league.
opto

had 'em for a year now and quite content with slow upwardly mobile progress I expected with the present announced increase in the MRSA scandal they may of risen, but unless people are aware of them then they'll not.The institutions are keeping a tight handle on them.

According to INTEK on A.D.F.V.N. here is the present breakdown of ownership as of the 7th Feb

Directors and key personnel = 45%
Institutions = 43%
Free float = 12%

So there ain't many around so plenty of buying will send it rising.

Thanks for that...I am not alone.Also bt. AMS at the same time; they flew up in a flurry and then landed back where I found them.This also has to be a good investment.UPANDDOWN...thankyou for info,did'nt realise they only have such a small free float.Does'nt this make them harder to sell in a falling mkt?Also,the spread is controlled more by THEM than us...(is'nt it anyway...so much for free market forces out there.)

rising again today until the last deal of the day they were up a further 1.5p on bid

they are just about the easiest share to sell, the mms will bite your hand off.
the Institutions just can't get enough of them and there are some big announcements in the pipeline.

The more I read about HCEG,the more impressed I am by their sensible way of conducting the business.They have more than doubled their mkt cap since the same time,last year.When investors worried about the amount of shares and warrants HCEG had in the market,the company reacted in the right way.When buying a new business,they usually buy around half that company and when the time is right buy out the remaining minority interest in return for shares in HCEG plus a cash consideration. Mr Mcgregor,the previous owner of Ebiox Ltd.,will be paid in tranches of shares depending upon the success of Ebiox Handrub.He will also receive royalties for the next five years,depending on sales.The fact that Mr Mcgregor has agreed to these terms shows how secure he feels about the future success of Ebiox wipes and sprays.In the case of Gordon Wood,the founder of SafaTec(Israel),the holding company for Ebiox and Optiscope that HCEG completed buying this year,he will not be able to sell any shares he receives as payment for a year from issue date.Mr Wood is now COO of HCEG.Did you know that Ebiox was first designed to counter chemical warfare agents?Ebiox IS potentially the blockbuster in their portfolio of products and they are expecting a favourable report from trial runs in NHS hospitals.But I see applications in the catering industry as well as in medical/laboratory situations.Plus,Ebiox is claimed to be effective against the SARS virus as well as PARVOVIRUS,affecting dogs.Two thirds of nurses questioned said that they were allergic to alcohol based hand washes.Ebiox Handrub demonstrated a 99.999% reduction in ALL test organisms within 30 seconds.What more can I say:This is no longer in the class of tiddler penny shares,it has the capacity to be a really good investment.Ethel...IMHO

HCEG are into all sorts of things from Optiscope thru to Airway devices.If you look at the websites of the various company's of which HCEG has an interest you'll be amazed at the numerous products they're involved with.They are far and away from a one product firm as seems to be the general consensus.It's still not too late and one to pack away for the long term.

Nice start to the day. At last we may see a re-rating

RNS Number:1608J
Healthcare Enterprise Group PLC
01 March 2005

Ebiox surface disinfectant, test results

Proven combatant ability against HIV and Avian Flu

Healthcare Enterprise Group PLC ("HCEG"), the international healthcare products
and Services Company announces that its TrionicTM product, from the Ebiox family of products, has passed tests proving virucidal efficacy against the HIV and
Avian Flu ( Bird Flu) viruses.

The tests, conducted by Microbiotest Inc of Sterling, Virginia, USA conclude that using Trionic in a range of different levels of dilution, applicable to the test, the two viruses became undetectable.

Reports this week surrounding the failure to reduce death rates from MRSA in the
UK and the need to remain vigilant with HIV, highlighted once again the need to
improve hygiene practices on our own doorstep.

However, the problem of cross contamination is much more widespread as evidenced by the growing fear surrounding the spread of Avian Flu around the world.

According to the World Health Organisation, Avian Flu viruses can be readily
transmitted from farm to farm by mechanical means, such as contaminated
equipment, vehicles and cages.

Stringent sanitary measures on farms can confer some degree of protection, including hand hygiene and surface cleaning and disinfection. HCEG recently completed agreement with Alpha Trading (Asia) Co Ltd covering the distribution of Ebiox throughout Asia and reports encouraging initial demand driven by the Avian Flu crisis.

TrionicTM is a highly effective disinfectant already proven to combat MRSA,
SARS and other pathogens.

The product offers significant safety advantages over all other commonly used disinfectants and does not contain alcohol, chlorine or other irritating vapours. Moreover, TrionicTM contains soil lifting agents and biocides, which allow removal of microbes down to the molecular level, by removing biofilms, which are believed to provide a rich breeding ground for the development of resistant bacteria.

Many of the disinfectants currently used are ineffective in dirty conditions, when soiling is present. TrionicTM works differently, cleaning, disinfecting and deodorising in one to provide complete decontamination.

Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:

"Avian Flu has been described as the number one health threat in the world and
huge resources are being channelled at controlling the disease which has a 76%
fatality rate.

As with HIV, MRSA, SARS and all other deadly diseases, the microbes can harbour on surface areas, hence the need to regularly decontaminate. TrionicTM, through its unique properties, eradicates all surface microbes and pathogens without the problem of resistant strains forming.

"We plan to market TrionicTM aggressively across all relevant industry sectors
internationally, thus affording rapid deployment to combat this serious
international problem."

Still motoring. Nothing to stop this now!!

yep Troys up around 15% and will rocket as can see no holding theses back especially with the FANTASTIC RNS above.

Pleased to be in on this...my original target reached...where do you expect the sp to go to in the short term?

Still steaming ahead !!

not long before 1 perhaps month or so

That will make a very nice start up&down

why did it jump 16% + today ? I'm not complaining, I've had a few for a year. There has not any news today - at least not on moneyam has there?

mgalbraith, have a look at Troys post 161

More to come I am sure :)

this from A.D.V.F.N. with REF to 161

Government unveils bird flu action plan

Adrian O'Dowd
Tuesday March 1, 2005

Major public venues such as cinemas, football grounds and schools could be closed to prevent the spread of a deadly new influenza that could kill around 50,000 people a year, the government warned today.
Public spaces could be closed to help minimise the expected pandemic of avian flu expected to hit the UK that could possibly more than quadruple the average of 12,000 people a year who die from flu.

The chief medical officer, Sir Liam Donaldson, said: "We must assume we will be unable to prevent it reaching the UK. When it does, its impact will be severe in the number of illnesses and the disruption to everyday life."

The Department of Health today announced it was buying 14.6 million courses of anti-viral drug oseltamivir (Tamiflu) at a cost of 200m over the next two financial years to prepare for the pandemic, which has been predicted as a near inevitability by the World Health Organisation. The drugs will help reduce the severity of the disease and help people fight it off.

As soon as the pandemic hits, a vaccine will be made to combat it, but this cannot be done until it actually emerges, said Sir Liam, and this could take four to six months to produce.

Another method of reducing the impact of the pandemic will be to close schools and large public events like concerts and football matches, and Sir Liam said: "This is a preventative strategy to take. Social intervention is to be kept very much in reserve. We do not want to see schools closing or social events stopping unless absolutely necessary."

The DoH was also planning to advise the general public to maintain good basic hygiene for example by washing hands, covering noses and mouths when coughing or sneezing, and avoiding crowds when possible. Announcements would be made to the public via newspapers, radio and television on the best course of action to take.

The health secretary, John Reid, said: "We have been working together with other countries and WHO to ensure the international communities are as prepared as can be. Around 25% of the UK population might be affected.

"It makes sense to ensure we in the UK are as prepared as we can be and have drugs for use against an influenza pandemic here."

Sir Liam added: "Depending on the size of the pandemic and the time of the year, it will inevitably put pressure on the NHS, but the NHS has shown it is now very good at dealing with winter pressures. There is better organisation and triaging. We think we have the infrastructure in place."

Mandatory quarantine or curfews mentioned in the DoH's document Pandemic Flu - UK Influenza Pandemic Contingency Plan were not considered to be necessary and are not covered by public health legislation.





http://dailynewspaper.co.uk/

Another great start to the day.

What a horrible scenario....everyone sitting at home with their Ebiox tissues to hand ,playing poker on line.This is obviously a devious scam by our overlords to keep us out of trouble!!Incidentally,the drug in question Tamiflu has not been one of Roche's best sellers so far (it protects against pneumonia type complications) and could shove the price of Roche shares up for those of you who can afford them!There were four large sell offs late yesterday in HCEG,I hope the sp continues to go up till Friday.Sometimes we get a five day run on this type of news .What is obvious is that this share is'nt just for share clubs,widows and orphans.Would'nt it be interesting if one of the big players tried to buy Ebiox off HCEG?What's going on with poor BQE all this time?
Thanks Troys,upanddown and ever optomist for being on this little thread.Ethel

1 here we go. I'm in for the long term on this one.

Just a whisker away from the 1 and then what's the target :-)

Spread has halved in the last hour.

25K buy just gone through @ 1

The HCEG site on Digitallook has been turned off for essential maintenance,I could do with some of that!

HCEG LOOKS LIKE IS GAINING MOMENTUM

Ethel

I do maintenance

I just knew that someone would rise to the occasion,and it is a man with lots of lolly,yippee....
Back to HCEG.Would like to know who is doing their Ebiox products' manufacturing.Is this outsourced?They have main offices in London,Los Angeles and Germany.Head office in Warrington.U.K.,export division in Essex.The SAFA products,bandages etc. are made in Thailand.This company is really diverse in healthcare products.You can buy flu jabs from them as well...useful against the forthcoming Sars epidemic maybe???
I suspect that this rally will not continue unless the big boys get in and /or there is a major commitment from the NHS.But,note the date of the first posting on this thread.Ebiox products ARE for sale....the stuff is brilliant but where are the big orders?Until there is financial proof of sucessful sales I shall pop in and out until the future of this wonderful company is more visible.

Are you selling Ethel? I suppose you can now that you have found your galant and wealthy knight :-))

Not yet,generally sell when I am still in the green.Expect a tumultuous crash down when sentiment turns,which is the wrong attitude to have but have been burnt like this before.My Morrisons and Compass shares rocketed down when the time came!!!That's why if the big boys are'nt in HCEG,then it should chug along with all the little investors buying.Really,why does'nt the Minister for health get on and buy gallons of Ebiox stuff and REALLY CLEAN UP the system??Ah..ah...who is the main provider of cleaning products to the NHS?Maybe there are contracts that still have time to run.Old boy network etc.
Maybe Lord le Dosh is already bethrothed,methinks he only does maintenance not regular servicing.

Ethel
Opto
I purchased my first HCEG shares in November 03 @ 1.65 sold just prior to consolidation and repurchased after the consolidation was completed. Up until the last three days these have allways been a good steady earner and were aquired for the medium to longer term. If we look at the fact that they have a great products base, are in to the american market, are graced with a no-nonsence management, I would say that IMO unless you are looking for a quick profit this company is money in the bank. If you want a secure punt hold on to your holding.

By the way the maintenance is costing me an arm and a leg

I bought at about 1.95 in Jan 03 then I kept buying as it dropped to 1.50's in spring and have watched it gradually rise (double+) as I Hoped/expected. I think this is worth holding and won't be worried by a drop for profit take. If there is no news for a while, it will probably drop off as the impatient sell but I've decided to keep this one for the long haul and hope I'll benefit from big dividends in a few years time.

You have done really well with your timing on these.I note that the spread has widened and there are little buyers at 103p.However,I just looked at all the red on the FTSE 100 and remembered the world outside the penny shares club.That world looks serious,today.Oil prices up again,Greensberg looking serious talking about financing America's debt.Iraq horrors,terrorist threats,projected food shortages throughout the world because of the weather we have forced upon our planet and I feel that we might be in for a downward re-adjustment in the stock market soon.The sentiment in the mainstream market affects that in the small caps territory despite the resilience of the latter.It is fairly easy to buy small caps,but often difficult to sell them in a falling market.
The sp has yet to find a lower resistance level which makes it hard to see how far it could go upto on enthusiasm alone(RE:DOO)!!!I was thinking of 70p as a retracement target price,but in view of the sp rise today,it makes it even harder to calculate what could happen.The same happened with MER last year it was and still is hard to calculate what the real value of this company is.The nice ride up was finally halted by various "people" saying enough is enough...your money would be better off here or there..the meddlers.

Another great start to the day !!

This has been brilliant,but we are pretty much alone on this thread,strange.Have a look at SPH,also good potential IMHO.

You are not alone.But for those of us who bought at 2p or so we are now only at 4.5p in old money,very nice but not exactly a ten bagger yet.Admittedly we have more security now that is no longer a penny share, but what are the chances of this ever reaching 5 to make it a genuine 10 bagger? Will now look at SPH and RGT

Bit like me and b####y Planestation!!I'm getting all excited here while there are loads of people still suffering losses.As this has gone on quite nicely all week I anticipate a top of 125p and then a sell off...let's see.
re SPH,there is a resistance at 140 which has been twice tested recently.See no reason why the sp can't reach 180p in medium term.

Lots of sellers today. Obviously many people reluctant to go long on this share.They seem to be happy to make a few pence on the weeek.But if you are looking for a company with prospects this is as good as you are likely to find.

a few buyers have returned at the end of the day so perhaps they may rise tommorrow.

I don't have real-time share prices,never saw sp touch 126p...was staring at 122.50p(bid 120p)..went to get a cuppa..came back and the bid was 114p,you can see the loop on the chart!!!That was really quick considering that the big boy's never really got on board.Double the volume today.Many more sellers of quantity than buyers.Maybe the sp will have another go upto 126p tomorrow with the small punters carrying on buying...maybe there will be some news??I sold my small investment today,wanted to lock in a decent profit.Shall definitely re-invest in HCEG...has a great future in front of it.
Ethel.Good luck all you long term holders!!

The best HCEG board by far is on ADVFN - excellent thread. A must for those seriously into this stock. It's free have a look.

sw

Seawatcher you are right, it is first class. And so are the shares.

Hi,

Just found this site a couple of days ago.

Have been watching HCEG with much interest and now at 126p buy @12.10pm

What are your views on continuing going north?http://HCEG

Yes, lots of posts on ADVFN. Even people thinking of shorting because its risen so much.Very risky to short on a Friday- there might be favourable press comment over the weekend.I know it is so tempting to take the profit but this sp.will rise and rise over the next 12 months imo.

Decided to join in on this ride. Hope it's not too bumpy.

Do not consider shorting this share! you will get your fingers burned. Go long instead.

I have a feeling that they will go to 150p.Never looked at the chart beyond this year,stupid me.This wonderful rise today has occured with sells almost double the buys today.Good on ya!!!
Mis ETHEL.

wrong thread.